Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma

Introduction: The best treatment for young patients with high-risk diffuse large B-cell lymphoma (DLBCL) is still a matter of debate. Results the phase 3 R-MegaCHOEP study showed promising results using etoposide in combination R-CHOP (R-CHOEP). Progression-free (PFS) and overall survival (OS) rates (18–60 years) (age-adjusted IPI 2, 3) DLBCL treated R-CHOEP were among reported such patients. Recently, polatuzumab vedotin R-CHP (pola-R-CHP) was approved based on data POLARIX that an improvement PFS following pola-R-CHP compared to 2–5. To obtain further insights into optimal (age ≤60 years), (aaIPI we retrospectively outcomes or R-CHOEP. Methods: Treatment consisted 6 cycles followed by 2 rituximab (R) given every weeks 8 CHOEP two plus R. Event-free (EFS), PFS, OS years aaIPI calculated major toxicities compared. Kaplan-Meier method used estimate EFS, each group. Hazard ratios 95% CI log-rank tests comparing calculated. P-values <0.05 considered significant. Results: 113 127 analyzed. Major patient characteristics differed more group showing (28% vs. 12%). Two-year EFS-, PFS-, OS-rates 65.9% (CI: 56.7%, 74.8%), 74.8% (66.5%, 83.0%), 88.3% (82.3%, 94.3%) as 70.5% (62.5%, 78.5%), 74.9% (67.3%, 82.6%), 84.6% (78.3%, 91.0%) no significant differences any these endpoints between regimens. Patients experienced hematological toxicity infections (29.9% ≥ grade R-CHOEP-treated 15.0% patients) 4 treatment-related deaths occurring pola-R-CHP, respectively. research funded by: This sponsored F. Hoffmann-La Roche Ltd. Keywords: Aggressive non-Hodgkin lymphoma, Combination Therapies Conflicts interests pertinent abstract. G. Lenz Consultant advisory role: Ltd., Gilead, Janssen, Bristol-Myers Squibb, Novartis, AbbVie, Incyte, Genmab, Constellation, ADC Therapeutics, Karyopharm, Miltenyi, PentixaPharm, Sobi, Immagene, Genase, Hexal/Sandoz, Lilly Research funding: Bayer, AstraZeneca, MorphoSys Educational grants: Other remuneration: Takeda, Hexal/Sandoz (Speaker's Bureau). (Expert Testimony) H. Tilly Celgene/Bristol-Myers Squibb Honoraria: Ltd./Genentech, Inc. Janssen M. Ziepert B. Altmann V. Craine Employment leadership position: Yan Stock ownership: C. Herbaux Janssen-Cilag, Gilead Sciences Takeda Nickelsen J. Hirata Genentech, D. Sahin Lee Morschhauser Inc., Celgene, Epizyme, Servier, Genmab Chugai, Eisai N. Schmitz Allogene, Miltenyi Allogene